With M&A and partnerships on the rise,the radiopharmaceutical sector is booming, offering significant investment options as it continues to expand swiftly.
North American nuclear medicine market, valued at USD 2.05B in 2023, is projected to grow at a 9.90% CAGR, driven by AI, hybrid imaging, and theranostics.
In a $547M deal, Bayer and NextRNA collaborate to develop small molecule cancer drugs targeting long non-coding RNA, with a focus on the high-need conditions.
Targeting aggressive lung cancer, GSKs $1.7B ADC has been granted FDA breakthrough status, launching a novel therapy for advanced-stage small-cell lung cancer.
In an effort to fund a wide pipeline of antibody-drug conjugates moving toward licensing, Duality Biotherapeutics has submitted paperwork for a Hong Kong IPO.
